Journal of Peking University(Health Sciences) >
Increased receptor activator of nuclear factor kappa B ligand expressed on B10 cells in rheumatoid arthritis
Received date: 2018-07-02
Online published: 2018-12-18
Supported by
Supported by the National Natural Science Foundation of China(81701614)
Objective: To detect receptor activator of nuclear factor kappa B ligand (RANKL) expressed on B10 cells in rheumatoid arthritis (RA) and to evaluate the correlation between RANKL-producing B10 cells in RA and clinical features and laboratory parameters, trying to reveal the possible role of B10 cells in the pathogenesis of RA and the potential mechanism of impaired immunosuppressive capacities.Methods:25 RA patients and 20 healthy volunteers were enrolled. These RA patients did not received treatment with glucocorticoids, disease-modifying anti-rheumatic drug and biologics during the recent half of a year. The levels of RANKL-producing B10 cells were measured by flow cytometry (FCM) and polymerase chain reaction (PCR). The correlation between the frequencies of RANKL-producing B10 cells in RA and clinical data, laboratory parameters were analyzed. The role of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) in inducing RANKL expression in B10 cells was evaluated by in vitro stimulation assay. Independent samples t test, Pearson and Spearman correlation were used for statistical analysis.Results:B10 cells were capable of producing RANKL at a low level in health controls. The frequencies of RANKL-producing B10 cells were markedly higher in RA patients than in health controls (3.65%±1.59% vs. 2.25%±0.68%, P<0.01). The frequencies of these cells correlated po-sitively with RA tender joint counts, swollen joint counts and disease activity score in 28 joints (DAS28) (r=0.479, P=0.035;r=0.519, P=0.008;r=0.526, P=0.019). However, no correlation was found between these cells and RA patient age, disease duration, or the levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA). After in vitro stimulation by TNF-α, but not IL-1β, B10 cells isolated from healthy donors demonstrated fundamentally upregulated expression of RANKL.Conclusion:Our studies showed the frequencies of RANKL-producing B10 cells were markedly higher in RA patients, and their frequencies were positively correlated with RA tender joint counts, swollen joint counts and DAS28. These findings suggested that B10 cells might be involved in RA bone destruction.
Key words： Arthritis,rheumatoid; B10 cells; RANK ligand; Bone destruction
Hong jiang LIU , Xiao feng GUO , Fan lei HU , Cui ping YAN , Xiang jun CUI , Xue liang YAN , Zhan guo LI , Yuan JIA , Shu lin ONG . Increased receptor activator of nuclear factor kappa B ligand expressed on B10 cells in rheumatoid arthritis[J]. Journal of Peking University(Health Sciences), 2018 , 50(6) : 968 -974 . DOI: 10.19723/j.issn.1671-167X.2018.06.005
| [1] | Mauri C, Bosma A . Immune regulatory function of B cells[J]. Annu Rev Immunol, 2012,30:221-241. |
| [2] | Kalampokis I, Yoshizaki A, Tedder TF . IL-10-producing regulatory B cells (B10 cells) in autoimmune disease[J]. Arthritis Res Ther, 2013,15(Suppl. 1):S1. |
| [3] | Iwata Y, Matsushita T, Horikawa M , et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells[J]. Blood, 2011,117(2):530-541. |
| [4] | Rosser EC, Mauri C . Regulatory B cells: origin, phenotype, and function[J]. Immunity, 2015,42(4):607-612. |
| [5] | Daien CI, Gailhac S, Mura T , et al. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity[J]. Arthritis Rheumatol, 2014,66(8):2037-2046. |
| [6] | Ma L, Liu B, Jiang Z , et al. Reduced numbers of regulatory B cells are negatively correlated with disease activity in patients with new-onset rheumatoid arthritis[J]. Clin Rheumatol, 2014,33(2):187-195. |
| [7] | Cui D, Zhang L, Chen J , et al. Changes in regulatory B cells and their relationship with rheumatoid arthritis disease activity[J]. Clin Exp Med, 2015,15(3):285-292. |
| [8] | Hirayama T, Danks L, Sabokbar A , et al. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis[J]. Rheumatology (Oxford), 2002,41(11):1232-1239. |
| [9] | Gravallese EM, Harada Y, Wang JT , et al. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis[J]. Am J Pathol, 1998,152(4):943-951. |
| [10] | Kong YY, Yoshida H, Sarosi I , et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis[J]. Nature, 1999,397(6717):315-323. |
| [11] | Schett G, Gravallese E . Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment[J]. Nat Rev Rheumatol, 2012,8(11):656-664. |
| [12] | Gravallese EM, Manning C, Tsay A , et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor[J]. Arthritis Rheum, 2000,43(2):250-258. |
| [13] | Yeo L, Toellner KM, Salmon M , et al. Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis[J]. Ann Rheum Dis, 2011,70(11):2022-2028. |
| [14] | Yeo L, Lom H, Juarez M , et al. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis[J]. Ann Rheum Dis, 2015,74(5):928-935. |
| [15] | Arnett FC, Edworthy SM, Bloch DA , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988,31(3):315-324. |
| [16] | Keystone E, Emery P, Peterfy CG , et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies[J]. Ann Rheum Dis, 2009,68(2):216-221. |
| [17] | Wheater G, Hogan VE, Teng YK , et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis[J]. Osteoporos Int, 2011,22(12):3067-3072. |
| [18] | Boumans MJ, Thurlings RM, Yeo L , et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis[J]. Ann Rheum Dis, 2012,71(1):108-113. |
| [19] | Harre U, Georgess D, Bang H , et al. Induction of osteoclasto-genesis and bone loss by human autoantibodies against citrullinated vimentin[J]. J Clin Invest, 2012,122(5):1791-1802. |
| [20] | Bugatti S, Caporali R, Manzo A , et al. Involvement of subchondral bone marrow in rheumatoid arthritis: lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment[J]. Arthritis Rheum, 2005,52(11):3448-3459. |
| [21] | Meednu N, Zhang H, Owen T , et al. Production of RANKL by memory B cells: a link between B cells and bone erosion in rheumatoid arthritis[J]. Arthritis Rheumatol, 2016,68(4):805-816. |
| [22] | Kobayashi K, Takahashi N, Jimi E , et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction[J]. J Exp Med, 2000,191(2):275-286. |
| [23] | Kitaura H, Kimura K, Ishida M , et al. Immunological reaction in TNF-alpha-mediated osteoclast formation and bone resorption in vitro and in vivo[J]. Clin Dev Immunol, 2013,2013:181849. |
| [24] | Heider U, Langelotz C, Jakob C , et al. Expression of receptor activator of nuclear factor kappa B ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma[J]. Clin Cancer Res, 2003,9(4):1436-1440. |
| [25] | Han X, Kawai T, Eastcott JW , et al. Bacterial-responsive B lymphocytes induce periodontal bone resorption[J]. J Immunol, 2006,176(1):625-631. |
| [26] | Onal M, Xiong J, Chen X , et al. Receptor activator of nuclear factor kappa B ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss[J]. J Biol Chem, 2012,287(35):29851-29860. |
| [27] | Titanji K, Vunnava A, Sheth AN , et al. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection[J]. PLoS Pathog, 2014,10(11):e1004497. |
| [28] | Manabe N, Kawaguchi H, Chikuda H , et al. Connection between B lymphocyte and osteoclast differentiation pathways[J]. J Immunol, 2001,167(5):2625-2631. |
| [29] | Pugliese LS, Goncalves TO, Popi AF , et al. B-1 lymphocytes differentiate into functional osteoclast-like cells[J]. Immunobiology, 2012,217(3):336-344. |
| [30] | Carter NA, Rosser EC, Mauri C . Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis[J]. Arthritis Res Ther, 2012,14(1):R32. |
| [31] | Yang M, Deng J, Liu Y , et al. IL-10-producing regulatory B10 cells ameliorate collagen-induced arthritis via suppressing Th17 cell generation[J]. Am J Pathol, 2012,180(6):2375-2385. |
/
| 〈 |
|
〉 |